ACADIA Pharmaceuticals Inc. (ACAD) Analysts See $-0.44 EPS

July 14, 2018 - By Megan Stone

Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.37, from 1.26 in 2017Q4. It dropped, as 24 investors sold ACADIA Pharmaceuticals Inc. shares while 59 reduced holdings. 21 funds opened positions while 53 raised stakes. 119.37 million shares or 1.72% more from 117.35 million shares in 2017Q4 were reported.
Aperio Ltd Company owns 17,593 shares or 0% of their US portfolio. Global X Mngmt invested in 1,706 shares or 0% of the stock. Alliancebernstein L P, New York-based fund reported 100,596 shares. The New York-based Perceptive Advisors Llc has invested 0.17% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Harvey Cap Mgmt stated it has 219,042 shares. Wells Fargo And Mn reported 184,464 shares. Deutsche Comml Bank Ag accumulated 1.06 million shares. Tci Wealth Advsrs reported 0.02% stake. Emory University reported 1.36% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Rhumbline Advisers owns 102,228 shares. Hightower Advsr Lc accumulated 15,695 shares. Garrison Bradford Associates invested 1.32% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Pub Employees Retirement System Of Ohio, Ohio-based fund reported 37,947 shares. Ghost Tree Cap Ltd Liability Corporation accumulated 1.82% or 400,000 shares. Barclays Pcl, United Kingdom-based fund reported 66,111 shares.

Since January 29, 2018, it had 1 insider purchase, and 1 sale for $949,145 activity. $1.18 million worth of stock was sold by Baity Glenn on Monday, January 29.

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $-0.44 EPS on August, 14.They anticipate $0.11 EPS change or 20.00 % from last quarter’s $-0.55 EPS. After having $-0.44 EPS previously, ACADIA Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.69% or $0.3 during the last trading session, reaching $17.46. About 2.45 million shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 32.66% since July 14, 2017 and is downtrending. It has underperformed by 45.23% the S&P500.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Among 2 analysts covering ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ACADIA Pharmaceuticals Inc had 2 analyst reports since April 10, 2018 according to SRatingsIntel. Needham maintained the stock with “Buy” rating in Tuesday, April 10 report. The firm has “Buy” rating given on Tuesday, April 10 by Cowen & Co.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $2.18 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

More notable recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: which released: “Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)” on July 13, 2018, also with their article: “PreMarket Prep Recap For July 5: Trading The Range In The S&P 500; Sean Udall Joins The Show” published on July 05, 2018, published: “Acadia Pharma +12% after FDA approves dosing, strength for Nuplazid” on June 29, 2018. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were released by: and their article: “The 3 Worst Biotech Stocks of 2018 (So Far)” published on July 08, 2018 as well as‘s news article titled: “Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm’s Investigation of Possible …” with publication date: July 11, 2018.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.